What do systematic reviews say?

Gemcitabine plus mitomycin C vs capecitabine plus mitomycin C

The review found no eligible studies for this question.

• Gemcitabine‐based chemotherapy for advanced biliary tract carcinomas 2018 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Gemcitabine plus mitomycin C vs capecitabine plus mitomycin C

The review found no eligible studies for this question.

• Gemcitabine‐based chemotherapy for advanced biliary tract carcinomas 2018 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Gemcitabine plus mitomycin C vs capecitabine plus mitomycin C

It is very uncertain whether gemcitabine plus mitomycin C changes overall response rate compared with capecitabine plus mitomycin C (very low certainty).

• Gemcitabine‐based chemotherapy for advanced biliary tract carcinomas 2018 · Cochrane Headline outcomes only
  RR 0.65 [0.25, 1.72]
  1 study · 51 participants
  Very low

Gemcitabine plus mitomycin C vs capecitabine plus mitomycin C

The review found no eligible studies for this question.

• Gemcitabine‐based chemotherapy for advanced biliary tract carcinomas 2018 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Gemcitabine plus mitomycin C vs capecitabine plus mitomycin C

It is very uncertain whether gemcitabine plus mitomycin C changes grade 1 ‐ 4 thrombocytopenia compared with capecitabine plus mitomycin C (very low certainty).

• Gemcitabine‐based chemotherapy for advanced biliary tract carcinomas 2018 · Cochrane Headline outcomes only
  RR 0.56 [0.29, 1.06]
  1 study · 47 participants
  Very low

Adjuvant S‐1 vs gemcitabine

It is very uncertain whether adjuvant S‐1 changes all‐cause mortality: 1‐year overall survival compared with gemcitabine (very low certainty).

• Postoperative adjuvant chemotherapy for resectable cholangiocarcinoma 2021 · Cochrane Headline outcomes only
  RR 0.38 [0.15, 0.96]
  1 study · 70 participants
  Very low

Adjuvant S‐1 vs gemcitabine

It is very uncertain whether adjuvant S‐1 changes all‐cause mortality: 2‐year overall survival compared with gemcitabine (very low certainty).

• Postoperative adjuvant chemotherapy for resectable cholangiocarcinoma 2021 · Cochrane Headline outcomes only
  RR 0.81 [0.58, 1.13]
  1 study · 70 participants
  Very low

Adjuvant S‐1 vs gemcitabine

• Postoperative adjuvant chemotherapy for resectable cholangiocarcinoma 2021 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 70 participants
  Very low